Navigation Links
Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
Date:10/23/2007

atients received two cycles of XL184 administered as a daily oral dose for 5 consecutive days with a 9-day observation period (0.08-11.52 mg/kg), or dosed daily (175 and 265 mg). Patients may remain on study in the absence of unacceptable toxicity or progressive disease. Primary endpoints of the trial are to evaluate the safety and tolerability of XL184, determine the MTD of XL184, and to evaluate the plasma pharmacokinetics of XL184 administered orally to patients with advanced malignancies. Secondary endpoints are to assess the preliminary anti-tumor activity after repeat administration of XL184, and to assess the effects of XL184 on vascular permeability in patients enrolled at the MTD. An evaluation of the pharmacodynamic effects of XL184 is being conducted as an exploratory endpoint.

About XL184

XL184 is a novel, orally administered, small molecule anticancer compound that in preclinical models has demonstrated potent inhibition of both MET and VEGFR2. XL184 has also exhibited potent inhibition of other important receptor tyrosine kinases (RTKs) that have been implicated in various forms of cancer including RET, KIT, FLT3, and TIE2. In preclinical efficacy studies, XL184 has inhibited tumor growth and induced the regression of large tumors in a broad range of human tumor xenograft models including breast cancer, lung cancer and glioma. In laboratory studies, XL184 has demonstrated good oral bioavailability and pharmacokinetic properties.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and ren
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
8. Media Advisory: ACC Updated Schedule
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
(Date:7/2/2015)... DURHAM, N.C. , July 2, 2015 ... its acquisition of assets related to the ion channel ... that had previously been obtained as part of Pfizer,s ... all of Pfizer,s rights to the "Icagen" name and ... will provide comprehensive services for ion channel and transporter ...
(Date:7/2/2015)... SHENZHEN, China , 2 de julio de 2015 ... secuenciación de ADN de alto rendimiento en ... por el American College of Pathologists (CAP). La instalación de ... el primer laboratorio de secuenciación de próxima generación que ... , cubriendo el más alto estándar en prácticas de ...
Breaking Medicine Technology:EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4BGI recibe la acreditación del College of American Pathologists (CAP) 2
... Denmark , July 29 AdvanDx ... for a fast, 90 minutes protocol for its Yeast ... the PNA FISH turn-around time from the original 2.5 ... from 90 minutes to 30 minutes.  Clinical validation studies ...
... FRANCISCO, Calif. , July 28 VaxGen, Inc . ... with diaDexus, Inc ., a diagnostics company focused on the development ... needs in cardiovascular disease.   , ... (Logo:   http://photos.prnewswire.com/prnh/19991112/VAXGENLOGO ) , ...
Cached Medicine Technology:AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH® 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH® 3AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH® 4VaxGen and diaDexus Complete Merger 2VaxGen and diaDexus Complete Merger 3VaxGen and diaDexus Complete Merger 4
(Date:7/2/2015)... Richmond, VA (PRWEB) , ... July 02, 2015 , ... ... New Albany, Mississippi. The opening is the first sweetFrog store located in Mississippi. The ... fastest growing companies in 2014. , The store, located at 104 Railroad Avenue, New ...
(Date:7/2/2015)... ... , ... Following the recent report by JAMA Internal Medicine published ... Americans, Samir Becic emphatically declared a war on obesity in the United States. , ... "We must understand the magnitude of this discovery. For that reason, I am declaring, ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Many Fourth of ... mind. That’s why Amica Insurance is sharing some tips to promote the ... approximately 230 people go to the emergency room daily with fireworks-related injuries in the ...
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured on NewsWatch ... products available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, ... versatile smart light bulbs on the market. , According to the U.S. Department of ...
(Date:7/2/2015)... ... July 02, 2015 , ... Global leader and compression innovator, SIGVARIS ... for men. , For style that’s quick on its feet, men will love ... great news for men everywhere because a simple change in socks can dramatically help ...
Breaking Medicine News(10 mins):Health News:sweetfrog Opens First Location in Mississippi 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3
... Individual Corporate Criminal Fine in History;Civil Settlement Up To ... Lilly and Company today agreed to plead guilty and ... uses not approved by the Food and Drug Administration ... This resolution includes a criminal fine of $515 million, ...
... Peptimmune, Inc. ("Peptimmune"), a privately held ... (NYSE: NVS ) an exclusive option to ... Peptimmune,s multiple sclerosis drug candidate. In a separate but ... L.P. made an equity investment in Peptimmune.In the event ...
... Adverse prescription-drug reactions,cost the United States healthcare ... and Drug Administration, and put numerous patients at ... , In a major ... (UH) in Cleveland has launched a state-of-the-art physicians,computer ...
... 2009 Paintballs can cause severe and ,visually ... settings without proper eye protection, reports a study ... Journal of Ophthalmology (www.AJO.com), published by Elsevier. ... cause tremendous damage to vital ocular structures often ...
... 15, 2009) Tufts University has received a grant ... design an obesity prevention program for new immigrants. ... the clinical trial will randomize more than 400 ... in Somerville, Mass., and follow them for two ...
... and national governments currently debating proposals to raise alcohol ... the February edition of Addiction journal finds ... people are to drink. And when they do drink, ... four decades, researchers documented a concrete association between the ...
Cached Medicine News:Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 2Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 3Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 4Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 5Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 6Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 7Health News:Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis 2Health News:University Hospitals and OnCallData Launch New Portal Combining State-of-the- Art Electronic Prescribing and Medication Reconciliation 2Health News:University Hospitals and OnCallData Launch New Portal Combining State-of-the- Art Electronic Prescribing and Medication Reconciliation 3Health News:Paintballs can cause 'devastating' eye injuries 2Health News:Tufts receives NIH grant to study obesity prevention in new immigrants 2Health News:Tufts receives NIH grant to study obesity prevention in new immigrants 3Health News:Alcohol taxes have clear effect on drinking 2
... DiffSpin Slide Spinner for technique ... to wedge smears.,DiffSpin is a compact, ... for the preparation of uniformly distributed ... Complete with a start-up supply of ...
... MP is a small, quiet, high-speed centrifuge. ... suspension system which results in nearly vibration- ... achieve both top speed and full breaking ... be changed with a simple push-on/ pull-off; ...
... to establish temporary internal drainage from the ... transplant. Non-radiopaque ink bands serve as a ... anticipate where the coil(s) will form as ... peel-open packages. Intended for one-time use. CAUTION: ...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: